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Abstract
BACKGROUND—The cost-effectiveness of early antiretroviral therapy (ART) in persons
infected with human immunodeficiency virus (HIV) in serodiscordant couples is not known.
Using a computer simulation of the progression of HIV infection and data from the HIV
Prevention Trials Network 052 study, we projected the cost-effectiveness of early ART for such
persons.
METHODS—For HIV-infected partners in serodiscordant couples in South Africa and India, we
compared the early initiation of ART with delayed ART. Five-year and lifetime outcomes
included cumulative HIV transmissions, life-years, costs, and cost-effectiveness. We classified
early ART as very cost-effective if its incremental cost-effectiveness ratio was less than the annual
per capita gross domestic product (GDP; $8,100 in South Africa and $1,500 in India), as cost-
effective if the ratio was less than three times the GDP, and as cost-saving if it resulted in a
decrease in total costs and an increase in life-years, as compared with delayed ART.
RESULTS—In South Africa, early ART prevented opportunistic diseases and was cost-saving
over a 5-year period; over a lifetime, it was very cost-effective ($590 per life-year saved). In India,
early ART was cost-effective ($1,800 per life-year saved) over a 5-year period and very cost-
effective ($530 per life-year saved) over a lifetime. In both countries, early ART prevented HIV
transmission over short periods, but longer survival attenuated this effect; the main driver of life-
years saved was a clinical benefit for treated patients. Early ART remained very cost-effective
over a lifetime under most modeled assumptions in the two countries.
CONCLUSIONS—In South Africa, early ART was cost-saving over a 5-year period. In both
South Africa and India, early ART was projected to be very cost-effective over a lifetime. With
individual, public health, and economic benefits, there is a compelling case for early ART for
serodiscordant couples in resource-limited settings. (Funded by the National Institute of Allergy
and Infectious Diseases and others.)
Walensky et al. Page 2













IN THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) Prevention Trials Network
(HPTN) 052 study,1 early antiretroviral therapy (ART), as compared with delayed ART, was
associated with a 96% relative reduction in the rate of linked transmission among
serodiscordant couples during 24 months of follow-up. (Early ART was defined as therapy
initiated when the CD4+ T-cell count ranged from 350 to 550 per cubic millimeter, and
delayed ART as therapy initiated when the CD4+ count was <250 per cubic millimeter.) The
trial also showed clear clinical benefits for patients with HIV infection in the early-ART
group, as compared with those in the delayed-ART group, since the early initiation of
therapy prevented both primary and secondary complications of HIV infection.2 Results
from observational studies have also supported the efficacy of early HIV treatment.3-6
Although the clinical efficacy of treatment as prevention may be consistent across settings,
the economic value may differ, owing to differences in resource utilization, labor costs, and
ability to pay (as it relates to different values of the national gross domestic product [GDP]).
We projected the cost-effectiveness of early ART, as compared with delayed ART, among
serodiscordant couples, accounting for both treatment and transmission effects in South
Africa and India, two of the nine countries that were included in the HPTN 052 study.
METHODS
ANALYTIC OVERVIEW
In collaboration with the HPTN 052 investigators, the Cost-Effectiveness of Preventing
AIDS Complications (CEPAC) International Group conducted a model-based analysis that
closely mirrored the HPTN 052 trial. We used a microsimulation model of HIV disease,
treatment, and transmission7-10 to compare early ART with delayed ART in serodiscordant
couples. We conducted analyses to determine whether regional differences in South Africa
and India had an effect on the value of early ART versus delayed ART. We evaluated the
following outcomes from a modified societal perspective (excluding time and productivity
costs): clinical outcomes (the rate of survival and per-person life expectancy in life-years),
transmission outcomes (first- and second-order transmission events), and economic outcome
(per-person HIV-related health care costs). We first simulated the trial period (24 months of
follow-up) and then projected these outcomes over a 5-year period and over a lifetime (i.e.,
until every member of the simulated index cohort died).
We calculated the incremental cost-effectiveness ratio of early ART, as compared with
delayed ART, as the change in cost divided by the change in life-years, accounting for both
the health gains and medical costs for the treated patient and for the timing, decreased
survival, and increased costs of the projected transmission events (see the Supplementary
Appendix, available with the full text of this article at NEJM.org). We classified early ART
as very cost-effective if the incremental cost-effectiveness ratio was less than the per capita
GDP in 2011 ($8,100 for South Africa and $1,500 for India) and as cost-effective if the
incremental cost-effectiveness ratio was less than three times the GDP.11-13 Early ART was
considered to be cost-saving, as compared with delayed ART, when it led to both a decrease
in total costs and an increase in life-years. For cost-effectiveness calculations, costs and life
expectancy of both index and transmitted cases were discounted (i.e., given less value in the
future) at an annual rate of 3%12; the event outcomes (number of transmissions and percent
survival) were not discounted.
CEPAC INTERNATIONAL MODEL
Disease Model—The CEPAC International model is a microsimulation of HIV disease
progression and treatment that is focused on resource-limited settings.7-10 Simulated patients
are generated with random draws of characteristics from distributions of age, sex, CD4+
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count, and HIV RNA level (see the Supplementary Appendix). The HIV RNA level
determines the monthly change in the CD4+ count. A lower count leads to a higher risk of
setting-specific opportunistic diseases and HIV-related mortality. The model simulates a
patient’s underlying CD4+ count and HIV RNA level; however, clinical decisions are based
on presentation with an opportunistic disease or on an observed CD4+ count and HIV RNA
level, which are measured on periodic laboratory testing (see the Supplementary Appendix).
According to the HPTN 052 study protocol, CD4+ counts and HIV RNA levels in the model
were monitored quarterly; when a patient met strategy-specific treatment criteria (e.g., a
CD4+ count of <250 per cubic millimeter in the delayed-ART group), ART was initiated.
Once patients were receiving ART, they had an initial probability of virologic suppression,
with a corresponding increase in CD4+ counts. Among these patients, there was a small
monthly probability of loss of treatment efficacy (late failure), resulting in virologic rebound
and subsequent decline in the CD4+ count. At the time of laboratory-confirmed treatment
failure, as defined in the trial,1 patients were started on a second-line protease inhibitor–
based drug regimen with an efficacy that was assumed to be equivalent to that of the first-
line therapy (see the Supplementary Appendix). Patients could be categorized as having
been lost to follow-up before starting ART or while receiving therapy; in the latter group,
therapy was discontinued. Patients who were lost to follow-up had a 50% probability of
returning to care during the month of an acute episode of an opportunistic disease.
Transmission Module—We used a transmission module to tally monthly transmission
events to primary and secondary partners and to project both the incident transmission from
the index patient (i.e., first-order transmission) and subsequent transmissions to other
uninfected partners (second-order transmission) (for details, see the Supplementary
Appendix). The module allowed for variation in the duration of primary partnerships and in
sexual activity outside those partnerships, age-adjusted sexual behaviors, and
transmissibility. For incident HIV cases, acute infection increased infectivity to future
uninfected partners (see the Supplementary Appendix). On resolution of acute disease,
previously uninfected incident cases — once HIV was detected — were eligible for the
same strategy (early vs. delayed ART) as the index case. In the case of secondary partners,
we assumed that early ART would benefit all partners of the HIV-infected person.
INPUT DATA
Cohort—Characteristics of the study cohort reflected the characteristics of all participants
in the HPTN 052 study. For patients in both South Africa and India, we used pooled
estimates of mean (±SD) age (33.7±8.5 years) and initial CD4+ count (449±120 per cubic
millimeter). Because there were significant differences between the two countries with
respect to patients’ sex and HIV RNA distributions, we used country-specific data for these
variables (Table 1).14-21
Natural History—We derived monthly rates of opportunistic diseases from the widely
reported Cape Town AIDS Cohort in South Africa and the Y.R. Gaitonde Centre for AIDS
Research and Education (YRG CARE) cohort in India.22,23 For patients who were receiving
treatment, the use of trimethoprim–sulfamethoxazole (which was initiated at a CD4+ count
of <200 per cubic millimeter)1,14,24,25 attenuated the frequency of some events.26
ART Efficacy and Loss to Follow-up—We derived data on the efficacy of ART and
loss to follow-up from the trial (see the Supplementary Appendix). At 48 weeks, the rate of
virologic suppression was 92%. The rate of later virologic failure was 1.4 cases per 100
person-years. The rate of loss to follow-up was 3.4 cases per 100 person-years.
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Transmission—Data from the HPTN 052 study showed that the average number of
secondary partners per month was 0.014 in South Africa and 0.007 in India. Within a
serodiscordant partnership, trial-derived transmission rates depended on the HIV RNA level
of the index patient, with rates ranging from 0.10 cases per 100 person-years for patients
with virologic suppression (<400 copies per milliliter) to 1.48 per 100 person-years for
patients without virologic suppression. We assumed that sexual activity was age-
dependent18 and that the average duration of the primary partnership was 15 years.15 We
also assumed that for the incident (first-order) cases that were not in primary partnerships,
the average number of partners per month was 2.0.27 We modeled a 5-month duration of
acute infection, during which infectivity increased by a factor of 26, as compared with
infectivity among patients without HIV RNA suppression.16,17
Costs—We calculated the costs of treating a patient with HIV infection by multiplying
resources used (e.g., inpatient days, outpatient visits, and laboratory tests) by country-
specific unit costs that included costs for professional time, supplies, and non-ART
medications, as well as capital costs; these values were derived from data obtained from
sources other than the HPTN 052 study.19,20 We derived ART costs from the World Health
Organization (WHO) Global Price Reporting Mechanism database (Table 1).21 We used
country-specific GDP deflators and the average 2011 exchange rate to convert all currencies
to 2011 U.S. dollars.11,28
Sensitivity and Scenario Analyses—We first conducted an analysis for the base-case
scenario, as defined by the input values described in Table 1. We then conducted one-way
sensitivity analyses of clinical, transmission-related, and cost variables to examine their
effect on four outcomes of delayed ART, as compared with early ART: the 5-year and
lifetime change in cumulative transmissions and the 5-year and lifetime incremental cost-
effectiveness ratio.
Since clinical trials probably represent the best-case scenario with regard to ART efficacy,
transmissions, and other outcomes, we examined two additional scenarios (multiway
sensitivity analyses) (Table S2 in the Supplementary Appendix). In the routine-care
scenario, we used a later presentation for care (mean CD4+ count per cubic millimeter, 195
in South Africa and 305 in India).23,29 For the two countries, we used a 48-week virologic
suppression rate of 74%, a later virologic failure rate of 9.5 cases per 100 person-years,30 a
rate for loss to follow-up of 10.0 cases per 100 person-years through the first year of ART
(and 3.2 per 100 person-years thereafter),31-33 and a slightly higher transmission rate (0.16
to 9.03 cases per 100 person-years).34 In the worst-case scenario, we incorporated cohort
characteristics that were similar to those in the routine-care scenario: a 48-week virologic
suppression rate of 65%, a later failure rate of 14.1 cases per 100 person-years,35 a rate of
loss to follow-up of 10.0 cases per 100 person-years in the first year of ART (and 5.1 per
100 person-years thereafter),31-33 and a transmission rate of 1.25 to 21.83 cases per 100
person-years.18
RESULTS
SIMULATION OF TRIAL PERIOD
On the basis of clinical and ART data from the HPTN 052 study, the model produced a
plausible replication of trial-based, 24-month immunologic outcomes (Fig. S1 in the
Supplementary Appendix).
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PROJECTED OUTCOMES FOR INDEX PATIENTS
Clinical Factors—In South Africa, the 5-year rate of survival among index patients
increased with early ART, as compared with delayed ART (93% vs. 83%). Over a lifetime,
the life expectancies with early ART, as compared with delayed ART, were 189.4 months
and 165.2 months, respectively. Clinical outcomes in India were qualitatively similar to
those in South Africa (Table 2).
Costs—In South Africa, early ART prevented many opportunistic diseases (e.g.,
tuberculosis), thus preventing comparatively high costs of care (Fig. S2 in the
Supplementary Appendix), a savings that more than outweighed ART costs. Consequently,
over a 5-year period, early ART and delayed ART in South Africa had similar per-person
costs (approximately $4,800). Over a lifetime, the longer survival that was associated with
early ART increased total costs, as compared with delayed ART ($16,600 vs. $15,100)
(Table 2).
In India, the average costs associated with medical care for opportunistic diseases, as
compared with costs associated with ART, are lower than those in South Africa (Fig. S2 in
the Supplementary Appendix). Although early ART prevented opportunistic diseases in
India, the cost savings did not outweigh the ART costs; thus, early ART led to higher total
costs than delayed ART over both a 5-year period ($2,200 vs. $1,800) and a lifetime ($8,400
vs. $7,300) (Table 2).
Transmissions—In South Africa, early ART resulted in an immediate, large decrease in
the number of projected transmissions (Fig. 1A, and Fig. S4A in the Supplementary
Appendix). The difference in transmission rates was attenuated over time, as more patients
started receiving therapy in the delayed-ART group. By year 6 after presentation, rates of
annual transmissions were greater in the early-ART group than in the delayed-ART group
because most patients in the delayed-ART group were receiving ART and some patients in
the early-ART group had begun to have virologic failure. However, rates of cumulative
transmissions in the early-ART group remained consistently lower than those in the delayed-
ART group throughout the lifetime of the index patient (Fig. 1B). Projected transmission
results were similar in the two countries (Fig. S3A, S3B, and S4B in the Supplementary
Appendix).
Cost-Effectiveness—When we included transmission-related life-months lost and costs
accrued over a 5-year period, early ART was cost-saving, as compared with delayed ART,
in South Africa. Over a lifetime, early ART was very cost-effective ($590 per life-year
saved) (Table 2, and Fig. S6 in the Supplementary Appendix). In India, early ART was cost-
effective over a 5-year period ($1,800 per life-year saved) and very cost-effective over a
lifetime ($530 per life-year saved) (Table 2, and Fig. S6 in the Supplementary Appendix).
In the two countries and over the two time periods, the clinical benefit to the index patient
who received early ART was much larger in magnitude than the clinical benefit associated
with the prevention of new transmissions. For example, for a patient receiving early ART in
South Africa, the 5-year increase in life expectancy of 3.2 months (from 51.7 to 54.9
months) was much larger than the clinical benefit associated with the prevention of new
transmissions, which resulted in 0.07 life-months gained (a decrease in life-months lost from
0.09 to 0.02).
SENSITIVITY ANALYSES
Transmissions—In the South African base-case scenario, early ART, as compared with
delayed ART, resulted in a relative reduction of 69% in the number of transmissions over a
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5-year period and of 13% over a lifetime (Table 2). Input values related to treatment —
specifically, changes in 48-week suppression rates, late virologic failure (after initial
suppression), and loss to follow-up — had the greatest effect on these results (Fig. S7A and
S7B in the Supplementary Appendix). Regardless of these variations, early ART
consistently resulted in fewer infections than delayed ART over the 5-year and lifetime
periods. Similar results were seen in India (Fig. S7C and S7D in the Supplementary
Appendix).
Cost-Effectiveness—In South Africa, in most of the ranges that we examined, early ART
was cost-saving over a 5-year period. Variation in several treatment-related variables
(including increased rates of late failure associated with poor ART adherence) moved the
incremental cost-effectiveness ratio for early ART from cost-saving to very cost-effective;
however, for transmission-related variables, these ratios were consistently cost-saving (Fig.
2A). Five-year results were also sensitive to these variables in India, where some variation
in treatment-related variables moved early ART from cost-effective to very cost-effective
(Fig. 2B). In one-way sensitivity analyses, early ART was very cost-effective over a lifetime
across all ranges of variables that were examined in the two countries (Fig. S8A and S8B in
the Supplementary Appendix).
SCENARIO ANALYSES
In the two countries and for both time periods, projected clinical outcomes were worse for
alternative scenarios in which there were lower rates of efficacy for ART, higher rates of
late virologic failure, and higher rates of loss to follow-up (see Table S3 for the routine-care
scenario and Table S4 for the worst-case scenario in the Supplementary Appendix). With
later ART initiation, less effective treatment, and higher transmission levels, early ART had
more modest benefits with respect to transmission at 5 years, with no benefit over a lifetime
(Fig. S5 in the Supplementary Appendix). Despite these changes in variables and subtle
differences in outcome, economic and policy conclusions were robust. In the base-case
scenario, as well as in the routine-care and worst-case scenarios, early ART at 5 years was
cost-saving in South Africa and cost-effective in India. In all scenarios and in both countries,
early ART was very cost-effective over a lifetime (Tables S3 and S4 in the Supplementary
Appendix).
DISCUSSION
With compelling evidence supporting the clinical and preventive benefits of early ART, the
focus is now on economic questions with respect to early ART.3-6 In a model-based analysis
projecting the clinical, population, and economic effects of the HPTN 052 study in South
Africa and India, we found that early ART substantially improved the rate of survival of
infected patients, greatly decreased the rate of early HIV transmissions, and provided an
excellent return on investment. We specifically chose to model these two countries because
they had the highest numbers of persons with HIV infection among the nine countries that
were evaluated in the HPTN 052 study and because South Africa and India were
representative of middle-income and lower-income countries, respectively (Table S5 in the
Supplementary Appendix).11 Over the first 5 years, the differences in costs of care and GDP
accounted for differences in the cost-effectiveness of early ART. In South Africa, early ART
was found to be cost-saving, whereas in India, early ART was cost-effective. Over the long
term, early ART was very cost-effective in both countries.
Data from the HPTN 052 study highlight the benefits of early ART with respect to both
morbidity and transmission. Early ART significantly increased the time to a diagnosis of
tuberculosis, a WHO stage 4 event, or secondary complications, as compared with delayed
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ART.2 In our model-based, longer-term projections, these delays in morbidity led to
substantial reductions in mortality — differences that were not detected in the short
timeframe of the HPTN 052 study. Indeed, these data and projections underscore that among
the greatest prevention effects of early ART is the durable prevention of opportunistic
diseases.
Our analyses show that the preventive value of early ART depends on the extent to which
patients remain in care and receive effective treatment. The capacity to maintain virologic
suppression among patients who are retained in care will determine the magnitude of long-
term benefits with respect to transmission.
Although our study shows that early ART is very cost-effective, a major challenge to its
implementation — in addition to the challenge of earlier HIV disease detection36 — is
affordability in resource-limited settings. This should not be the case in South Africa. Over
the first 5 years, the cost of early ART is more than offset by the prevention of common,
expensive-to-treat opportunistic diseases; the opportunity to offset those costs is lost when
ART is delayed. In India, upfront expenditures will be needed to implement early ART.
Our results are more conservative — with respect to cumulative transmissions prevented by
early ART — than those modeled in studies reported previously.37,38 The reason for this is
that we accounted for the individual benefit of early ART and the monthly changes in
virologic-based transmissions associated with HIV detection, virologic suppression and
rebound, and loss to follow-up. We also specifically chose to examine countries with
different care and cost structures in order to show the generalizability of these results in two
very different resource-limited settings.
In the HPTN 052 study, a total of 39 HIV transmission events were reported, with definitive
HIV phylogenetic data available for 36 of these events. Of the latter transmission events, 7
(19%) were not phylogenetically linked to the primary partner and were presumed to have
been acquired from secondary partners,39 whose characteristics are unknown. If many of
these secondary partners would not be eligible for ART under a policy of early ART for
serodiscordant couples, then we may have overestimated the preventive effect of this policy.
Alternatively, if the secondary partners would be eligible for ART as members of
serodiscordant couples, then we may have underestimated the preventive effect of early
ART. Regardless of the direction of this bias, our results and sensitivity analyses showed
that early ART would be very cost-effective.
Our study has several limitations. First, we intentionally adhered closely to the design,
population, and data of the HPTN 052 study.1 Although we have examined the potential
generalizability of the conclusions in routine-care and worst-case scenarios, we cannot be
sure that the results are representative of care in nontrial settings or of patients with HIV
who are not in regular serodiscordant partnerships. Second, in the scenario analyses, we did
not consider the possibility of increased drug resistance because of poor adherence. Third,
since HIV-infected patients were already identified in the HPTN 052 study, we consider our
study to be an analysis of “treatment as prevention” rather than an analysis of “test and
treat.” Fourth, although we excluded productivity and other nonmedical economic benefits
of prevented transmissions, the inclusion of such factors would make the results even more
economically attractive.40 Fifth, despite the many benefits of modeling HIV progression
together with transmissions, such a complex model is not easily conducive to probabilistic
sensitivity analysis. Finally, we limited the analysis to first-order and second-order
transmissions from the index patient; as indicated by the modest effect of second-order
transmissions, the inclusion of more distal transmissions would no doubt have a minimal
effect on the results.
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In conclusion, our analysis using the clinical data from the HPTN 052 study and published
data from cohorts in South Africa and India shows that early ART provides substantial
individual and population benefits over delayed ART. The ultimate preventive value of early
ART is a shared responsibility of providers and patients, and patients who remain in care
with virologic suppression will glean the maximum long-term preventive effect of early
ART. Early ART also has major economic benefits and is very cost-effective — results that
are robust across settings and assumptions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. HIV Transmissions among Serodiscordant Couples in South Africa, According to the
Strategy for the Initiation of Antiretroviral Therapy (ART).
Shown are results for a modeled cohort of 1 million HIV-infected index patients in
serodiscordant relationships, according to whether they received no ART, delayed ART, or
early ART. Panel A shows the total number of transmissions per year, and Panel B shows
the cumulative number of transmissions. The number of transmissions includes both first-
order and second-order transmissions.
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Figure 2. Results of One-Way Sensitivity Analyses.
Shown are the effects of various treatment and transmission variables on the incremental
cost-effectiveness ratio (the change in cost divided by the change in life-years) for early
ART, as compared with delayed ART, over a 5-year period in South Africa (Panel A) and
India (Panel B). ART efficacy was defined as HIV RNA suppression at 48 weeks. In these
tornado diagrams (so named because the data are listed vertically in a funnel pattern, with
the most important variables at the top), the solid vertical line indicates the incremental cost-
effectiveness ratio for the base-case scenario in the study. The length of the horizontal bars
indicates the range of incremental cost-effectiveness ratios over the specified range of
variable values; the longer the bar, the greater the sensitivity of the incremental cost-
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effectiveness ratio to that variable. To the right of the horizontal bars in Panel A, the range
of values that were examined is shown in parentheses, with the value producing the lower
incremental cost-effectiveness ratio listed first. Incremental cost-effectiveness ratios that met
the definition of cost-saving (which was defined as both a decrease in total costs and an
increase in life-years) are not shown in the tornado diagram. Instead, the cost-saving range
for incremental cost-effectiveness ratios is provided to the left of the horizontal bars. The
dashed vertical black line indicates the gross domestic product (GDP) of the country (the
threshold for being very cost-effective), and the dashed vertical red line represents three
times the GDP of the country (the threshold for being cost-effective, which is shown for
India only). The GDPs are shown in dollars (see the Methods section). In South Africa,
numerous ranges of values that were examined, including all transmission variables, showed
that early ART was cost-saving over a 5-year period. In India, early ART, as compared with
delayed ART, was found to be cost-effective over a 5-year period for the base case; with
variation in some treatment variables, early ART was very cost-effective (<$1,500 per life-
year saved). OD denotes opportunistic disease, and PY person-year.
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Table 1
Base-Case Input Data for Analysis of the Cost-Effectiveness of Early ART in the HPTN 052 Trial.*
Variable Base-Case Value† Range
South Africa India
Cohort characteristic
Age (yr) 33.7±8.5 33.7±8.5
Initial CD4+ count (cells/mm3) 449±120 449±120
Sex (%)
  Male 42 67
  Female 58 33
Efficacy of first- and second-line ART
Patients with HIV RNA suppression at 48 wk (%)‡ 92 92 69–100
Increase in CD4+ count at 48 wk (cells/mm3) 206 206
Rate of failure after 48 wk (no./100 person-yr) 1.4 1.4 0–14.1
Rate of loss to follow-up (no./100 person-yr) 3.4 3.4 0–10.0
Transmission
Average no. of secondary partners/mo§ 0.014 0.007
No. of transmissions/partner/100 person-yr¶
  Patients with suppression of HIV RNA 0.10 0.10
  Patients without suppression of HIV RNA 1.48 1.48
Average duration of primary partnership (yr) 15 15 5–100
Average duration of acute infection (mo) 5 5 0–12
Infectivity multiplier for acute infection∥ 26 26 0–50
Relative sexual activity according to age**
  15–24 yr 1.10 1.10
  25–29 yr 0.99 0.99
  30–34 yr 1.00 1.00
  >35 yr 0.82 0.82
Costs (2011 U.S. $)
Acute episode of opportunistic disease 309–1048 43–313 Base case × 0.25–4.00
Annual routine care 293–2390 90–311 Base case × 0.25–4.00
CD4+ test 14 6 Base case × 0.50–2.00
HIV RNA test 68 47 Base case × 0.50–2.00
Annual ART
  First-line 153 135 Base case × 0.25–1.00
  Second-line 520 561 Base case × 0.25–1.00
*
Plus–minus values are means ±SD. Sources of data are as follows: cohort characteristics, efficacy of first- and second-line antiretroviral therapy
(ART), and transmission per partner, ClinicalTrials.gov14; partnership duration, Lurie et al.15; duration of acute infection, Powers et al.16; acute
infection infectivity multiplier, Hollingsworth et al.17; sexual activity and age, Gray et al.18; costs, Médecins sans Frontières and Health Systems
Trust19 and YRG CARE20; and first- and second-line ART cost, World Health Organization.21
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†
For variables in which between-group differences were significant, characteristics are reported separately for the 954 African participants and the
531 Asian participants; otherwise, values are pooled estimates for the two regions. ART efficacy, rates of loss to follow-up, and transmission rates
were calculated for 1763 patients from all sites including those in North and South America. Additional details of the data analysis are provided in
the Supplementary Appendix.
‡
For the proportion of patients with HIV RNA suppression at 48 weeks, the 95% confidence interval was 90 to 94%.
§
For the average number of secondary partners per month (i.e., partners outside the primary relationship), 95% confidence intervals were 0.010 to
0.019 for South Africa and 0.003 to 0.012 for India.
¶
For the number of transmissions per partner per 100 person-yr, 95% confidence intervals were 0.012 to 0.372 for patients with HIV RNA
suppression and 0.978 to 2.158 for those without HIV RNA suppression.
∥
The infectivity multiplier for acute infection was applied to the transmission rate for patients without HIV RNA suppression.
**
Age groups do not include children up to the age of 14 years. The reference group was patients between the ages of 30 and 34 years.
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Table 2




















% mo 2011 U.S. $ no. (% change) mo 2011 U.S. $
South Africa
5-year period
  Delayed ART 83 51.7§ 4,800¶ 0.04 0.09 80 NA
  Early ART 93 54.9§ 4,800¶ 0.01 (−69) 0.02 20 Cost-saving
Lifetime period
  Delayed ART NA 165.2 15,100 0.08 5.26 760 NA
  Early ART NA 189.4 16,600 0.07 (−13) 2.64 560 590
  Alternative scenarios
    Routine care 630∥
    Worst case 550∥
India
5-year period
  Delayed ART 87 52.8§ 1,800 0.04 0.06 30 NA
  Early ART 94 55.1§ 2,200 0.01 (−66) 0.01 10 1,800
Lifetime period
  Delayed ART NA 182.6 7,300 0.08 3.83 370 NA
  Early ART NA 202.6 8,400 0.07 (−13) 1.95 290 530
  Alternative scenarios
    Routine care 560∥
    Worst case 480∥
*
NA denotes not applicable.
†
The overall incremental cost-effectiveness ratio was calculated as the difference in costs for the index patient plus the difference in the increase in
costs due to transmission divided by the difference in life expectancy for the index patients plus the difference in life-months lost due to
transmission, all discounted at 3% per year.
‡
The percent change in transmissions per index patient is indicated for early ART, as compared with delayed ART, and was calculated before
rounding.
§
Life expectancy for the 5-year period indicates the average duration of survival through 5 years.
¶
Costs are the same for delayed and early ART because of rounding. Unrounded values are $4,766 for delayed ART and $4,780 for early ART.
∥
Additional details of the results of the routine-care and worst-case scenarios are provided in Tables S3 and S4, respectively, in the Supplementary
Appendix.
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